No Data
No Data
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Viking Therapeutics, Inc. (VKTX): One of Oppenheimer's Top Stock Picks For the Next 12 Months
Why Viking Therapeutics Stock Got Thrashed on Tuesday
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
No Data